Stockreport

Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy

Scholar Rock Holding Corporation  (SRRK) 
Last scholar rock holding corporation earnings: 11/12 07:30 am Check Earnings Report
PDF - All doses were generally well tolerated, no dose limiting toxicities observed including at the Part B dose of 1500 mg- Biomarker data consistent with target engagement [Read more]